区域多中心重点监控药物目录的遴选方法及其监管策略
投稿时间:2019-08-12  修订日期:2019-08-20  点此下载全文
引用本文:
摘要点击次数: 32
全文下载次数: 0
作者单位E-mail
李睿旻 第二军医大学药学院药事管理教研室 daynes77@163.com 
杨樟卫 上海第四人民医院信息科  
中文摘要:目的 对辅助用药加强监管,降低不合理的医疗支出,提高临床合理医疗用药水平。方法 利用区域范围内集成的医疗数据库以及标准化的药品基础信息库,对辅助用药的市场品种占有情况及其在区域范围内医疗机构临床消耗情况进行分析,并比较2015年与实施监管后的2018年的数据。结果 获得区域范围内近200所医疗机构的药物临床应用信息化监测结果,组织专家进行集中评议。确定首批纳入区域范围内医疗机构重点监控的药品80种,并探讨了基于医疗大数据的遴选区域范围内重点监控药品目录的方法。临床重点监控药品不合理使用情况得到改善。结论 经过国家出台相关政策以及各地落实整改措施,不断强化监管,使得重点监控药品不合理使用情况得到了一定程度的改善。
中文关键词:辅助用药  重点监控药品  遴选方法
 
Selection method of key monitoring drug list in regional context and the supervision strategy
Abstract:Objective To reduce the unreasonable medical expenditure and improve the level of clinical rational drug use by strengthening the supervision of adjuvant drug use. Methods Using the regionally integrated medical database and standardized basic drug information database, the market share of adjuvant drugs varieties and their clinical consumption in regionally medical institutions were collected and analyzed. The data of 2015 and 2018 after the implementation of supervision were compared. Results The monitoring results of clinical application adjuvant drugs in nearly 200 medical institutions of the region were obtained. After expert review, the selection method of key monitoring drug list based on the medical big data was discussed. The first batch of 80 drugs in the key monitoring of regional medical institutions was confirmed. Improper use of key clinical monitoring drugs has been improved. Conclusion Through the introduction of relevant policies by the state and the implementation of rectification measures in various regions, the unreasonable use of key monitoring drugs has been improved to some extent.
keywords:supplementary medication  key monitoring  selection method
  查看/发表评论  下载PDF阅读器
相关附件:   万方20190812(10.75%)  万方20190820(10.75%)
关闭

分享按钮